One year of effective AIDS prevention therapy with a single medication, early clinical results are positive

Today, Merck & Co.

With the emergence of "cocktail therapy", AIDS has changed from a disease-causing disease that has become a fascinating disease to a chronic disease that can be controlled by drugs

Islatravir is an innovative NRTTI developed by Merck.

In this double-blind, placebo-controlled phase 1 clinical trial, 24 healthy participants implanted an implant containing different doses of islatravir in the upper arm, which can slowly release the drug in the body to achieve long-term maintenance drug treatment The effect of concentration

The test results showed that the three different doses of implants maintained the concentration of islatravir above the level of antiviral efficacy within 12 weeks

Note: This article is intended to introduce medical and health research, not to recommend treatment options

Reference materials:

[1] Merck Presents Results from Phase 1 Trial Evaluating Investigational Islatravir Subdermal Implant for the Prevention of HIV-1 Infection at CROI 2021.